Keyword: Neurocrine Biosciences
The drug comfortably beat placebo against a slew of efficacy endpoints and posted comparable safety and tolerability to the control.
Neurocrine Biosciences' congenital adrenal hyperplasia treatment significantly lowered levels of two types of hormones in most patients.
The deal sees Neurocrine commit to $1.7 billion in milestones in return for Parkinson’s disease program VY-AADC and other assets.
The collaboration gives Neurocrine a potential source of small molecules to treat disorders of the central nervous system.
The FDA will make its decision on AbbVie's elagolix to Q3, as it needs more time to review liver function tests.
Novartis poached Pfizer oncology head Liz Barrett, Ed Kaye became Stoke Therapeutics' CEO, and Perrigo hired Uwe Röhrhoff as CEO.
Neurocrine Biosciences has published a journal paper about its phase 3 trial of tardive dyskinesia candidate Ingrezza.
In our EuroBiotech roundup this week, Actelion reveals financial details of spinout, Novo A/S invests in Evotec and BIAL offloads Parkinson’s drug rights.
A phase 2 trial of Neurocrine’s Ingrezza in Tourette syndrome has missed its primary endpoint.
Teva has posted positive Phase III data for its involuntary twitch candidate deutetrabenazine as its gears up for a 2016 FDA filing--putting it a few months behind rival biotech Neurocrine to be the first to market a new med for the condition.